Expert Outlook: Nurix Therapeutics Through The Eyes Of 14 Analysts

In the last three months, 14 analysts have published ratings on Nurix Therapeutics NRIX, offering a diverse range of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Nurix Therapeutics, presenting an average target of $28.5, a high estimate of $35.00, and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 4.28% from the previous average price target of $27.33.

Decoding Analyst Ratings: A Detailed Look

The standing of Nurix Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nurix Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nurix Therapeutics compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Nurix Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.

For valuable insights into Nurix Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Nurix Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Nurix Therapeutics: Delving into Financials

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: Nurix Therapeutics displayed positive results in 3 months. As of 29 February, 2024, the company achieved a solid revenue growth rate of approximately 30.75%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Nurix Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -250.33% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Nurix Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -22.49%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Nurix Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -12.43%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Nurix Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.17.

What Are Analyst Ratings?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.